Results 141 to 150 of about 236,394 (247)

Mechanism and target treatment of primary immunodeficiency diseases with systemic lupus erythematosus-like phenotype. [PDF]

Pediatr Discov
Liu S, Zhang Z, Tang X, Zhao X, An Y.
europepmc   +1 more source

Extended High‐Risk HPV Genotyping With BD Onclarity Enhances Anal Cancer Screening Among High‐Risk Populations: A Cross‐Sectional Study

Diagnostic Cytopathology, EarlyView.
ABSTRACT Background Anal cancer rates are rising among women, immunocompromised individuals, and Men who have sex with Men (MSM), independent of HIV status. While high‐resolution anoscopy remains the diagnostic standard, limited access has increased interest in alternative screening.
Daisy Maharjan, Joshua Waters, Melissa Randolph, Benjamin Shuler, Julie Borum, Sheila Segura   +5 more
wiley   +1 more source

Screening for primary immunodeficiency diseases by next-generation sequencing in early life. [PDF]

Clin Transl Immunology, 2020
Sun J, Yang L, Lu Y, Wang H, Peng X, Dong X, Cheng G, Cao Y, Wu B, Wang X, Zhou W.   +10 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases. [PDF]

J Clin Immunol
Patel NC, Walter JE, Wasserman RL, Rubinstein A, Kankirawatana S, Shepherd MW, Greco E, Li Z, Russo-Schwarzbaum S, Saeed-Khawaja S, McCoy B, Yel L.   +11 more
europepmc   +1 more source

A British Pharmacological Society Position Statement on Medications in Pregnancy and Lactation

British Journal of Clinical Pharmacology, EarlyView.
Agnesa Mustafa, Cleodie C. Swire, Reya V. Shah, Bernadette Jenner, Rory H. McLean, Muhammad Shamsher Ahmed, Adrie Bekker, Julia Zöllner, Rachel K. Scott, Robert R. Bies, Sara K. Quinney, Dagan O. Lonsdale, Emma Forton Magavern, Catriona Waitt, Anita Banerjee   +14 more
wiley   +1 more source

Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study. [PDF]

J Clin Immunol
Rubinstein A, Mabudian M, McNeil D, Patel NC, Wasserman RL, Gupta S, Carrasco P, Chen J, Garcia E, Nagy A, Yel L.   +10 more
europepmc   +1 more source

Resource‐Adapted Triage Strategies for Women Testing HPV Positive With Self‐Collected Vaginal Samples in Cameroon

International Journal of Cancer, EarlyView.
Although human papillomavirus (HPV) testing is recommended for cervical cancer screening in low‐ and middle‐income countries, optimal management of HPV‐positive women remains undetermined, particularly in resource‐limited settings. Here, using data from the 3T study involving women in Cameroon, the authors evaluated the ability of extended HPV ...
Micol Murtas, Pierre Vassilakos, Ania Wisniak, Ketty Hu, Marc Arbyn, Gilles W. Tankeu Happi, Esther Abatsong, François Marcel Ndam Nsangou, Jean‐Christophe Tille, Essia Saiji, Bruno Kenfack, Patrick Petignat   +11 more
wiley   +1 more source

HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial

International Journal of Cancer, EarlyView.
ABSTRACT Evidence on the comparative effectiveness of HPV testing versus cytology specifically in women aged ≥ 50 years who are approaching screening cessation remains limited. This analysis included 6471 women aged ≥ 50 at baseline screening in the HPV FOCAL randomized clinical trial. Women were randomly allocated to receive cytology (Control Group, n 
Md Saiful Alam, Laurie W. Smith, Lovedeep Gondara, Darrel Cook, Ruth Elwood Martin, Stuart Peacock, Lily Proctor, Gavin Stuart, David Patrick, Eduardo L. Franco, Mel Krajden, Anna Gottschlich, Gina S. Ogilvie   +12 more
wiley   +1 more source